- Home
- BJDX vs ADTX Comparison
BJDX vs ADTX Comparison
Compare BJDX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- ADTX
- Stock Information
- Founded
- BJDX 2015
- ADTX 2017
- Country
- BJDX United States
- ADTX United States
- Employees
- BJDX N/A
- ADTX N/A
- Industry
- BJDX Medical Specialities
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- ADTX Health Care
- Exchange
- BJDX Nasdaq
- ADTX Nasdaq
- Market Cap
- BJDX 2.9M
- ADTX 3.1M
- IPO Year
- BJDX 2021
- ADTX 2020
- Fundamental
- Price
- BJDX $1.62
- ADTX $1.25
- Analyst Decision
- BJDX
- ADTX
- Analyst Count
- BJDX 0
- ADTX 0
- Target Price
- BJDX N/A
- ADTX N/A
- AVG Volume (30 Days)
- BJDX 2.1M
- ADTX 1.4M
- Earning Date
- BJDX 08-13-2025
- ADTX 08-18-2025
- Dividend Yield
- BJDX N/A
- ADTX N/A
- EPS Growth
- BJDX N/A
- ADTX N/A
- EPS
- BJDX N/A
- ADTX N/A
- Revenue
- BJDX N/A
- ADTX $55,323.00
- Revenue This Year
- BJDX N/A
- ADTX $15,768.94
- Revenue Next Year
- BJDX $55.56
- ADTX N/A
- P/E Ratio
- BJDX N/A
- ADTX N/A
- Revenue Growth
- BJDX N/A
- ADTX N/A
- 52 Week Low
- BJDX $1.46
- ADTX $1.11
- 52 Week High
- BJDX $37.50
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- BJDX 45.25
- ADTX 36.53
- Support Level
- BJDX $1.59
- ADTX $1.11
- Resistance Level
- BJDX $1.72
- ADTX $2.19
- Average True Range (ATR)
- BJDX 0.09
- ADTX 0.17
- MACD
- BJDX 0.01
- ADTX 0.04
- Stochastic Oscillator
- BJDX 43.33
- ADTX 12.96
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.